Loading
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Latest filing published 03 Jun 2024 for Corbus Pharmaceuticals Holdings, Inc..
Filing timeline
BuySaleAvery W. Catlin
Insider track record
Disclosed buys
5
Disclosed sells
0
Signal history
Closed purchases
Market purchases
5
Positive at T+90
50%
Median T+90
+2.9%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -10.9%Entry US$193.50 · Close at T+365 US$172.50
- -12.5%Entry US$240.00 · Close at T+365 US$210.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Avery W. Catlin: trading record in brief
Avery W. Catlin discloses dealings in 3 companies, chiefly Provention Bio, Inc., Celldex Therapeutics, Inc. and Corbus Pharmaceuticals Holdings, Inc. Between 9 March 2016 and 30 May 2024, the trades on record add up to 14 filings.
The open-market record is one-sided, with 5 purchases worth €87k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 4 option exercises.
The median purchase comes to €14k. 4 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The latest filing, published on 3 June 2024, reports a share grant in Corbus Pharmaceuticals Holdings, Inc. The most recent open-market purchase was published on 27 December 2018, 2,857 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Avery W. Catlin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
2,783 shares0Common Stock, par value $0.0001 per shareSEC:0000950170-24-068035:0
10,000 sharesCommon StockSEC:0001493152-23-013910:1
10,000 sharesCommon StockSEC:0001493152-23-013910:0
10,000 shares0Common StockSEC:0001493152-23-012387:1
10,000 shares0Common StockSEC:0001493152-23-012387:0
5,000 shares@ US$1.9018.9% of flowCommon StockSEC:0001493152-18-018016:0
Canonical exit: 24 Mar 2019 (T+90)
5,000 shares@ US$1.8518.3% of flowCommon StockSEC:0001493152-18-018016:1
Canonical exit: 26 Mar 2019 (T+90)
10,000 shares@ US$3.1562.7% of flowCommon StockSEC:0001493152-18-015651:0
Canonical exit: 7 Feb 2019 (T+90)
5,000 shares@ US$6.1566.6% of flowCommon StockSEC:0001209191-17-031737:0
Canonical exit: 9 Aug 2017 (T+90)
2,000 shares@ US$7.5533.4% of flowCommon StockSEC:0001209191-16-151670:0
Canonical exit: 20 Feb 2017 (T+90)
10,000 shares@ US$2.8020.0% of flowCommon Stock, par value $0.001 per shareSEC:0001179110-16-029382:0
20,000 shares@ US$2.8040.2% of flowCommon Stock, par value $0.001 per shareSEC:0001179110-16-026065:0
2,847 shares@ US$4.509.2% of flowCommon Stock, par value $0.001 per shareSEC:0001179110-16-026065:1
15,000 shares@ US$2.8030.6% of flowCommon Stock, par value $0.001 per shareSEC:0001179110-16-021475:0
14 of 14 declarations
